CDA | Evidence Driven
CDA | Evidence Driven

Palivizumab For Infection Prevention in Inuit Infants: A Review of the Clinical Effectiveness and Cost-Effectiveness

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1217-000

Question

  1. What is the clinical effectiveness of universal versus high risk palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants?
  2. What is the clinical effectiveness of seasonal versus year-round palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants?
  3. What is the cost- effectiveness of universal versus high risk palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants?
  4. What is the cost-effectiveness of seasonal (~6months) versus year-round palivizumab prophylaxis for respiratory syncytial virus prevention in Inuit infants

Key Message

No relevant literature was identified regarding the comparative clinical effectiveness of universal versus high-risk palivizumab or seasonal versus year-round palivizumab prophylaxis in Inuit children up to 4 years of age. Additionally, no relevant literature was identified regarding the comparative cost effectiveness of universal versus high-risk palivizumab or seasonal versus year-round palivizumab prophylaxis in Inuit children up to 4 years of age.

Files

Palivizumab For Infection Prevention in Inuit Infants: A Review of the Clinical Effectiveness and Cost-Effectiveness Rapid Response December 17, 2019 View PDF

Related Content

Last Updated : February 24, 2020